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Introduction
Deep vein thrombosis (DVT) is an important cause of morbidity 
and mortality with an estimated annual incidence of 0.67 to 1.0 per 
1000 among the general population in Western countries.
1-3) Pulmo-
nary embolism and post-phlebitic syndrome are the recognized 
complications. DVT may be caused by hereditary or acquired defects 
in the coagulation-anticoagulation pathway. Risk factors include 
prolonged non-ambulation, recent surgery, obesity, prior DVT, fe-
male sex hormone therapy, post-partum status, lower limb trauma, 
neoplastic disease and stroke. Recurrent DVT, a positive family his-
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Case
A 40-year-old non-smoker, non-diabetic, normotensive male pre-
sented with swelling and aching pain of the left lower limb extend-
ing from the left thigh to the ankle over one week. Upon examina-
tion, his pulse was 80 beats per minute and his blood pressure was 
140/85 mm Hg. The left lower limb with dusky blue discoloration of 
skin was diffusely swollen, warm, and exquisitely tender to touch. 
Arterial pulses in the legs were palpable. Three years ago, he devel-
oped a similar illness in the right leg, and was diagnosed as a case 
of DVT (Fig. 1).
Initial heparin therapy was followed by warfarin, which was dis-
continued after three months. Within two years the patient had DVT 
in the left lower limb (Figs. 2 and 3). The patient was prescribed an 
oral anticoagulant that was discontinued after several months.
There was no ulceration or gangrenous changes, nor was there any 
lymphadenopathy. Examination of the precordium revealed normal 
findings. Other systems were also normal. There was no neurological 
deficit. Fundoscopy was normal.
A duplex study of the lower limb vessels showed acute DVT in-
volving the left femoro-popliteal segment. CT angiography revealed 
normal pulmonary arteries (Fig. 4). Blood sugar, renal and liver func-
tion tests, serum electrolytes and calcium were normal. A haemo-
gram including platelet count, urinalysis, chest radiograph and echo-
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for filaria was negative. Because of the recurrence of venous throm-
boembolism (VTE), it was decided to search for any coagulation ab-
normality. Therefore, the blood coagulation profile was studied four 
weeks after the onset of DVT. Platelet count, bleeding time, clotting 
time and prothrombin time (PT) were normal. In addition, plasma 
fibrinogen and homocysteine levels were within normal range, and 
antithrombin activity in the blood was also normal. Conversely, the 
protein C activity was 58% (normal range: 70-140%), and the pro-
tein S activity was greatly reduced to 17% (normal range: 54-
137%). Ideally, coagulation assay should be conducted one month 
after completion of a course of anticoagulation, but considering the 
number and frequency of recurrence of DVT, and associated risks of 
life-threatening complications like pulmonary thromboembolism, 
anticoagulant therapy was not stopped.
In the acute setting, the patient was managed according to stan-
dard protocols, including elevation of the affected limb. Additionally, 
60 mg of enoxapain was administered subcutaneously every 12 
hours for one week, and this was overlapped with 5 mg warfarin ev-
eryday 72 hours after the onset of low-molecular-weight heparin 
therapy. The international normalized ratio (INR) was kept between 
2 and 3. The patient gradually improved and was discharged with 
warfarin. In a subsequent visit one month later, the INR was found 
to be 2.8; therefore, the patient was advised to continue oral anti-
coagulant therapy indefinitely.
Factor V Leiden and mutant prothrombin (Prothrombin 20210A) 
assay could not be done because these tests are not available in 
Bangladesh.
During follow-up over the next two-years, the patient was do-
ing well and did not have any complaints related to DVT. 
Discussion
Thrombophilia is the term used to describe predisposition to an 
increased risk of venous and occasionally arterial thromboembolism 
owing to haematological abnormalities.
5) This condition may be ac-
quired or hereditary. A genetic predisposition to thrombophilia has 
been identified in up to one-third of unselected patients with VTE 
and more than one-half of cases with familial thrombosis.
6)7) There 
may also be an inability of the body to produce adequate amounts 
of normal protein, or the body may produce abnormal protein that 
Fig. 4. Normal pulmonary arteries shown on the CT angiogram. Fig. 1. Left popliteal venous thrombosis.
Fig. 3. Incompletely recanalized left common femoral vein.
Fig. 2. Incompletely recanalized left external iliac vein.347 Afzalur Rahman, et al.
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does not function normally. Multiple defects can often be found in 
patients with the most marked thrombotic predispositions.
6)8) The 
presence of factor V Leiden, prothrombin gene mutation, anti-
thrombin III, protein C or protein S deficiency, hyperhomocysteinemia, 
hyperfibrinogenemia and elevated lipoprotein (a) are important 
causes of inherited thrombophilia.
Deficiencies of the endogenous anticoagulants, protein C, pro-
tein S and antithrombin III, are usually polygenic and have an au-
tosomal dominant inheritance with variable penetrance.
9) The ag-
gregate prevalence of the three conditions is approximately 7% in 
DVT patients.
10)11) Their deficiency increases the risk of venous th-
romboembolism. Protein C is made in the liver and is vitamin K de-
pendent. It acts to inactivate factor V and factor VIII. This protein 
also requires protein S as a cofactor and is activated by thrombin.
12) 
Protein C deficiency is observed in 1 in 200 to 1 in 300 healthy sub-
jects, many of whom remain asymptomatic.
13) The protein S is vita-
min K dependent and is synthesized by hepatocytes and megakary-
ocytes. Its deficiency has a prevalence of 1 to 2% in patients with 
DVT.
10)11) Antithrombin, which is made in the liver and endothelial 
cells, inactivates thrombin and other serine proteases. The preval-
ence of antithrombin III deficiency in the general population is 
0.02%, and in patients with a history of VTE is upto 4%.
14) In the case 
presented here, both protein C and protein S were deficient, which 
presumably made the patient more likely to develop recurrent DVT. 
Hao et al.
15) reported a case of a 44-year-old Japanese male who had 
three events of DVT within four years and was later found to have 
antithrombin deficiency.
The prevalence of factor V Leiden is 2-15% in the general popu-
lation,
14) but it is rare in native Africans and Asians.
16) DVT is the 
most common clinical manifestation of factor V Leiden. Prothrom-
bin G20210A is seen in 1-4% of general population,
14) and patients 
with the 20210A allele have significantly higher levels of plasma pro-
thrombin, which is believed to mediate the procoagulant effect.
9)
Hyperhomocysteinemia may be caused by abnormal homocyste-
ine metabolism due to genetic or nutritional defects.
17) There is in-
creased risk of both venous and arterial thrombosis.
9)
The first step in the diagnostic approach to all patients with ve-
nous thrombosis consists of a careful review of their history and 
physical examination combined with routine laboratory testing to 
characterize the severity of the thrombotic condition and deter-
mine the presence of any of the acquired causes of hypercoagula-
bility. The second step is to consider screening for the causes of he-
reditary and acquired thrombophilia in selected patients.
18) Indi-
cations for thrombophilia screening are 1) all patients with a first 
episode of spontaneous VTE, 2) patients with VTE under the age of 
50 years, even when they have a transient predisposing factor, 3) 
patients with VTE whose only risk factor is oral contraceptive thera-
py, estrogen replacement therapy or pregnancy, 4) patients with 
recurrent VTE, irrespective of risk factors, 5) patients with recurrent 
superficial thrombophlebitis without cancer and in the absence of 
varicose veins, 6) patients with VTE at unusual sites such as the 
cerebral venous sinus, mesenteric or hepatic veins and retinal vein 
occlusion under the age of 50 years, 7) patients with warfarin-induc-
ed skin necrosis or neonates with purpura fulminans not related to 
sepsis, 8) asymptomatic first degree relatives of individuals with 
proven symptomatic thrombophilia, 9) two consecutive or three non-
consecutive abortions at any gestational age or one fetal death af-
ter the 20th week, 10) severe pre-eclampsia, 11) children with VTE.
5)
Functional, immunological and molecular tests are available for 
laboratory evaluation of hereditary thrombophilia. Functional and 
immunological investigations are used for antithrombin, protein S 
or protein C deficiency and factor V Leiden. Their sensitivity and spe-
cificity are variable and are influenced by pregnancy, hepatic insuf-
ficiency and medications. Molecular tests are gene specific and more 
sensitive and specific and available for factor V Leiden and mutant 
prothrombin 20210A.
5) A full blood count, platelet count, PT, activat-
ed partial thromboplastin time (aPPT) and thrombin clotting time 
(TCT) should be conducted routinely. Liver function tests and blood 
urea and electrolytes are also indicated.
14) Blood counts may indicate 
myeloproliferative disorders, while APTT may be helpful in antiph-
ospholipid antibody syndrome, PT for interpretation of low protein 
C or protein S, and TCT for dysfibrinogenemia. Antiphospholipid an-
tibodies should also be included. Further investigations under ap-
propriate circumstances include assays for antithrombin, protein C 
and protein S, modified APC/SR test for factor V Leiden and poly-
merase chain reaction (PCR)-based assay for prothrombin G20210A. 
Factor VIII, homocysteine and fibrinogen assays are the second-
line tests for thrombophilia.
14) Polymerase chain reaction for factor 
V Leiden or prothrombin 20210A can be conducted at any time.
5) 
Conversely, antithrombin, protein C and protein S assays are best de-
layed until at least one month after completion of anticoagulation.
14)
Heparin, either unfractionated or low-molecular-weight, and war-
farin are the mainstays of treatment of acute DVT. The duration of 
secondary prophylaxis with warfarin depends on the presence of 
risk factors associated with recurrent DVT. Thrombophilia due to de-
ficiency of antithrombin, protein C or protein S, homozygosity for fac-
tor V Leiden or prothrombin G20210A, presence of cardiolipin anti-
bodies or lupus anticoagulant, elevated factor VIII or homocysteine 
and combined defects requires prophylaxis with warfarin indefi-
nitely. INR is kept between 2 and 3.
19) In a patient with recurrent DVT 
with thrombophilia, secondary prophylaxis with warfarin is of the 
utmost importance. The repeated episodes of DVT observed in the 
case presented here could probably have been prevented if warfarin 
were continued indefinitely after the first recurrence.348  Recurrent Deep Vein Thrombosis
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In conclusion, in patients with recurrence or unusual clinical 
presentation of DVT, hereditary coagulation defects should be sus-
pected. Laboratory tests during the acute episode may produce 
considerable confusion; therefore, they should be conducted at least 
one month after the cessation of anticoagulant therapy. In the 
presence of significant hereditary thrombophilia, secondary pro-
phylaxis with warfarin is lifelong in most cases. 
References
1. White RH. The epidemiology of venous thromboembolism. Circulation 
2003;107(23 Suppl 1):I4-8.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton 
LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary 
embolism: a 25-year population-based study. Arch Intern Med 1998; 
158:585-93.
3. Carter CJ. Epidemiology of venous thromboembolism. In: Hull RD, Pineo 
GF, editors. Disorders of Thrombosis. Philadelphia: WB Saunders;1996. 
p.159-74.
4. Maheshwari A, Mehrotra A, Henry R, et al. Deep veins thrombosis. Risk 
and management. In: Abela GS, editor. Peripheral Vascular Disease: Ba-
sic Diagnostic and Therapeutic Approaches. Philadelphia: WB Saun-
ders;2004. p.452-60.
5. Nicolaides AN, Breddin HK, Carpentier P, et al. Thrombophilia and ve-
nous thromboembolism. International Consensus Statement. Guide-
lines according to scientific evidence. Int Angiol 2005;24:1-26.
6. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 
20210A allele of the prothrombin gene increases the risk of thrombosis 
in subjects with familial thrombophilia. Thrmb Haemost 1997;78: 
1426-9.
7. Price DT, Ridker PM. Factor V Leiden mutation and the risks for throm-
boembolic disease: a clinical perspective. Ann Intern Med 1997;127: 
895-903.
8. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb 
Haemost 1997;78:297-301.
9. Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombo-
philia and venous thromboembolism. Am J Respir Crit Care Med 1998; 
158:1369-73.
10. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies 
of coagulation-inhibiting and fibrinolytic proteins in outpatients with 
deep-vein thrombosis. N Engl J Med 1990;323:1512-6.
11. Pabinger I, Brucker S, Kyrle PA, et al. Hereditary deficiency of antith-
rombin III, protein C and protein S: prevalence in patients with a histo-
ry of venous thrombosis and criteria for rational patient screening. Blo-
od Coagul Fibrinolysis 1992;3:547-53.
12. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001; 
161:2433-9.
13. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects 
with heterozygous protein C deficiency. N Engl J Med 1987;317:991-6.
14. Walker ID. Inherited thrombophilia. In: Hoffbrand AV, Catovsky D, Tud-
denham EG, editors. Postgraduate Haematology. Oxford: Blackwell; 
2005. p.885-99.
15. Hao WR, Kao PF, Leong YL, et al. Recurrent deep vein thrombosis caus-
ed by inherited coagulopathy in a Japanese male. Acta Cardiol Sin 
2008;24:157-60.
16. Rees CD, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 
1995;346:1133-4.
17. D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 
1997;90:1-11.
18. Bauer KA. The thrombophilias: well-defined risk factors with uncertain 
therapeutic implications. Ann Intern Med 2001;135:367-73.
19. Schulman S. Management of venous thromboembolism. In: Hoffbrand 
AV, Catovsky D, Tuddenham EG, editors. Postgraduate Haematology. 
Oxford: Blackwell;2005. p.912-24.